Pakistan Institute of Living and Learning

pill.org.pk

Total trials

58

Active

19

Phase 3

2

Total enrollment

42,689

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 1 of 1 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Standardised pharmacological treatment1

Next readouts

  • 2028-12-30

Top conditions

  • Depression10
  • Psychosis7
  • Schizophrenia6
  • Schizoaffective Disorder6
  • Maternal Depression5
  • Self Harm5
  • Suicidal Ideation4
  • Schizophreniform Disorder4

Frequently asked questions about Pakistan Institute of Living and Learning

How many clinical trials does Pakistan Institute of Living and Learning have on ClinicalTrials.gov?
Pakistan Institute of Living and Learning is listed as the lead sponsor on 58 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
How many of Pakistan Institute of Living and Learning's trials are in Phase 3?
2 of Pakistan Institute of Living and Learning's trials are in Phase 3, spread across 1 active drug program.
What therapeutic areas does Pakistan Institute of Living and Learning focus on?
Pakistan Institute of Living and Learning's most-studied conditions on ClinicalTrials.gov are Depression, Psychosis, Schizophrenia, Schizoaffective Disorder, Maternal Depression.
When are Pakistan Institute of Living and Learning's next clinical trial readouts?
Pakistan Institute of Living and Learning has 1 upcoming primary-completion readout tracked here; the soonest is “Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan”, expected around 2028-12-30.